• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

FLUVOXAMINE Drug Record

  • Summary
  • Interactions
  • Claims
  • FLUVOXAMINE chembl:CHEMBL814 Approved

    Alternate Names:

    N06AB08
    FLUVOXAMINE
    U-23000
    FLUVOXAMINUM
    FLUVOXAMINA
    LUVOX®
    drugbank:00176
    pubchem.compound:5324346
    chembl:CHEMBL814
    rxcui:42355
    chemidplus:54739-18-3

    Drug Info:

    Drug Class antidepressive agents, second-generation
    Year of Approval 1994
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antidepressant
    (3 More Sources)

    Publications:

    Benedetti F et al., 2010, Effect of catechol-O-methyltransferase Val(108/158)Met polymorphism on antidepressant efficacy of fluvoxamine., Eur Psychiatry
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Williams et al., 2010, Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)., Cochrane Database Syst Rev
    Miolo et al., 2002, Photoisomerization of fluvoxamine generates an isomer that has reduced activity on the 5-hydroxytryptamine transporter and does not affect cell proliferation., Eur. J. Pharmacol.
    Millan et al., 2003, Blockade of serotonin 5-HT1B and 5-HT2A receptors suppresses the induction of locomotor activity by 5-HT reuptake inhibitors, citalopram and fluvoxamine, in NMRI mice exposed to a novel environment: a comparison to other 5-HT receptor subtypes., Psychopharmacology (Berl.)
    Suhara et al., 2003, High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography., Arch. Gen. Psychiatry
    Dell'Osso et al., 2005, Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder., Expert Opin Pharmacother
    Irons, 2005, Fluvoxamine in the treatment of anxiety disorders., Neuropsychiatr Dis Treat
    Inoue, 2004, [Analysis and its application for prevention of side-effects of drugs and for evaluation of drug responsiveness]., Yakugaku Zasshi
    McMahon et al., 2001, Role of 5-HT(2a) and 5-HT(2B/2C) receptors in the behavioral interactions between serotonin and catecholamine reuptake inhibitors., Neuropsychopharmacology
    Kakiuchi et al., 2001, Effects of aging on serotonin transporter availability and its response to fluvoxamine in the living brain: PET study with [(11)C](+)McN5652 and [(11)C](-)McN5652 in conscious monkeys., Synapse
    Yoshida et al., 2002, Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients., Prog. Neuropsychopharmacol. Biol. Psychiatry
    Carrillo JA et al., 1996, Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity., Clin Pharmacol Ther
    Ozdemir V et al., 2001, Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C-->A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine., J Clin Psychopharmacol
    Kurose K et al., 2012, Genome-wide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort with major depression., Psychiatry Res
    Niitsu T et al., 2013, Pharmacogenetics in major depression: a comprehensive meta-analysis., Prog Neuropsychopharmacol Biol Psychiatry
    Ishiguro S et al., 2011, Determinants of pharmacodynamic trajectory of the therapeutic response to paroxetine in Japanese patients with panic disorder., Eur J Clin Pharmacol
    Yevtushenko OO et al., 2010, Early response to selective serotonin reuptake inhibitors in panic disorder is associated with a functional 5-HT1A receptor gene polymorphism., J Affect Disord
    Illi A et al., 2009, 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression., Neuroreport
    Kato M et al., 2009, Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder., Am J Med Genet B Neuropsychiatr Genet
    Baune BT et al., 2008, Serotonin receptor 1A-1019C/G variant: impact on antidepressant pharmacoresponse in melancholic depression?, Neurosci Lett
    Drago A et al., 2008, 5-HT1A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies., Int J Neuropsychopharmacol
    Kato M et al., 2009, 5-HT2A gene variants influence specific and different aspects of antidepressant response in Japanese and Italian mood disorder patients., Psychiatry Res
    Kato M et al., 2006, Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients., Neuropsychobiology
    Suzuki Y et al., 2006, Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patients., Neuropsychopharmacology
    Breitenstein B et al., 2016, Association of ABCB1 gene variants, plasma antidepressant concentration, and treatment response: Results from a randomized clinical study., J Psychiatr Res
    de Klerk OL et al., 2013, ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder., Pharmacogenomics J
    Uhr M et al., 2008, Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression., Neuron
  • FLUVOXAMINE   MDGA2

    Interaction Score: 3.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22445761


    Sources:
    PharmGKB

  • FLUVOXAMINE   SLC6A4

    Interaction Score: 1.19

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name fluvoxamine , fluvoxamine-CR,Luvox
    Novel drug target Established target

    PMIDs:
    20687077 12208313 12721776 12695316 16316311 18568110 15170064 11166521 11304754 11817517


    Sources:
    TdgClinicalTrial TEND

  • FLUVOXAMINE   HTR1A

    Interaction Score: 0.74

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23733030 21688171 19800133 19590397 18484082 18387740 18047755


    Sources:
    PharmGKB

  • FLUVOXAMINE   COMT

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20619611


    Sources:
    PharmGKB

  • FLUVOXAMINE   FGF2

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • FLUVOXAMINE   HTR2A

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19361869 16874005 16205777


    Sources:
    PharmGKB

  • FLUVOXAMINE   ABCB1

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26704739 22641028 18215618


    Sources:
    PharmGKB

  • FLUVOXAMINE   CYP1A2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8823236 11763009


    Sources:
    PharmGKB

  • FLUVOXAMINE   CYP2C9

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • FLUVOXAMINE   CYP2C19

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • FLUVOXAMINE   CYP3A4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • FLUVOXAMINE   CYP2D6

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    FDA

  • TEND: FLUVOXAMINE

    • Version: 01-August-2011

    Alternate Names:
    FLUVOXAMINE Primary Drug Name

    Drug Info:
    Year of Approval 1994
    Drug Class antidepressive agents, second-generation

    Publications:

  • TdgClinicalTrial: FLUVOXAMINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antidepressant
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • DTC: FLUVOXAMINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL814 ChEMBL Drug ID

    Drug Info:

    Publications:
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

  • PharmGKB: fluvoxamine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Benedetti F et al., 2010, Effect of catechol-O-methyltransferase Val(108/158)Met polymorphism on antidepressant efficacy of fluvoxamine., Eur Psychiatry
    Ozdemir V et al., 2001, Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C-->A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine., J Clin Psychopharmacol
    Carrillo JA et al., 1996, Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity., Clin Pharmacol Ther

  • TTD: Fluvoxamine

    • Version: 2020.06.01

    Alternate Names:
    D03HFG TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL814

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Fluvoxamine

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21